Patents by Inventor Daniel E. FELSING

Daniel E. FELSING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic g-protein-coupled receptor 52 (GPR52) agonists
    Patent number: 12441686
    Abstract: Embodiments are directed to novel GPR52 activators. In particular, a series of novel 1-(pyrimidin-4-yl)indoline-4-carboxamide analogs that have been identified as potent and selective GPR52 agonists. The optimized GPR52 agonist that, for example, can be used as a valuable pharmacological tool or a drug candidate for investigating the physiological and therapeutic potential of GPR52 activation for various human diseases.
    Type: Grant
    Filed: August 27, 2023
    Date of Patent: October 14, 2025
    Assignee: Board of Regents, The Univeristy of Texas System
    Inventors: Jia Zhou, John A. Allen, Pingyuan Wang, Daniel E. Felsing
  • HETEROCYCLIC G-PROTEIN-COUPLED RECEPTOR 52 (GPR52) AGONISTS
    Publication number: 20240059655
    Abstract: Embodiments are directed to novel GPR52 activators. In particular, a series of novel 1-(pyrimidin-4-yl)indoline-4-carboxamide analogs that have been identified as potent and selective GPR52 agonists. The optimized GPR52 agonist that, for example, can be used as a valuable pharmacological tool or a drug candidate for investigating the physiological and therapeutic potential of GPR52 activation for various human diseases.
    Type: Application
    Filed: August 27, 2023
    Publication date: February 22, 2024
    Inventors: Jia ZHOU, John A. ALLEN, Pingyuan WANG, Daniel E. FELSING
  • Heterocyclic g-protein-coupled receptor 52 (GPR52) agonists
    Patent number: 11773065
    Abstract: Embodiments are directed to novel GPR52 activators. In particular, a series of novel 1-(pyrimidin-4-yl)indoline-4-carboxamide analogs that have been identified as potent and selective GPR52 agonists. The optimized GPR52 agonist that, for example, can be used as a valuable pharmacological tool or a drug candidate for investigating the physiological and therapeutic potential of GPR52 activation for various human diseases.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: October 3, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jia Zhou, John A. Allen, Pingyuan Wang, Daniel E. Felsing
  • HETEROCYCLIC G-PROTEIN-COUPLED RECEPTOR 52 (GPR52) AGONISTS
    Publication number: 20220112164
    Abstract: Embodiments are directed to novel GPR52 activators. In particular, a series of novel 1-(pyrimidin-4-yl)indoline-4-carboxamide analogs that have been identified as potent and selective GPR52 agonists. The optimized GPR52 agonist that, for example, can be used as a valuable pharmacological tool or a drug candidate for investigating the physiological and therapeutic potential of GPR52 activation for various human diseases.
    Type: Application
    Filed: October 12, 2021
    Publication date: April 14, 2022
    Inventors: Jia ZHOU, John A. ALLEN, Pingyuan WANG, Daniel E. FELSING